Please login to the form below
cladribine
This page shows the latest cladribine news and features for those working in and with pharma, biotech and healthcare.
MS and cholesterol drugs picked for new UK rapid uptake push
Merck’s Mavenclad (cladribine) for treating highly active relapsing-remitting multiple sclerosis in adults - A drug for multiple sclerosis with a novel mode of action, high efficacy and a low treatment
Latest news
-
Sanofi licences Principia MS drug in $805m deal
The three established players in the oral MS therapy category are also about to see additional competition from new entrant Merck KGaA, which bagged EU approval for Mavenclad (cladribine) in August.
-
Merck mulls sale of consumer health division
The news comes a few days after Merck picked up an important new approval for its pharma division in Europe, with the EMA clearing Mavenclad (cladribine) for the treatment of
-
Merck gets CHMP backing for long-delayed oral MS drug
Cladribine, which will be branded as Mavenclad, was originally rejected by the committee in 2010. ... The company thinks oral cladribine has a key differentiator from its rivals, which require daily dosing.
-
Avelumab costs peg back profit at Merck KGaA
Avelumab and other pipeline candidates such as oral MS therapy cladribine have assumed even more importance for Merck since it abandoned plans to seek approval of evofosfamide in advanced soft tissue
-
Merck's pharma unit faces tougher 2017 as fertility boost recedes
Top of that list is oral MS therapy cladribine, which was submitted for approval in the EU in June, and according to Kuhnert is proceeding through regulatory review as expected.
More from news
Approximately 2 fully matching, plus 25 partially matching documents found.
Latest appointments
-
XenoPort appoints chief medical officer
Prior to joining Biogen Idec Dr Kim was with Merck Serono, serving as medical director for the phase III programme of cladribine, which failed to impress in MS.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
-
Account Director, Medical Education
-
Salary TBC
-
Account Manager / Account Director
-
Competative
- Senior Account Manager, Rare Diseases – Medical Communications, ...
-
Excellent package
-
Medical Writer
-
Salary TBC
- Global Business Development Director – Health Education
-
excellent commission
- Editorial Assistant Medical Education Agency
-
£25, 000 - £26, 000
-
Associate Director
-
£75, 000-90, 000
- Account Manager / Senior Account Manager
-
35, 000-40, 000
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
- Senior Account Director development role to Business Director, H...
-
Excellent package
-
Senior Medical Writer
-
Salary TBC
- Engagement Expert, Healthcare Brand Communications, London
-
Excellent package
Subscribe to our email news alerts
- Europe closer to biosimilar rule change, despite fierce resistance from pharma
- FDA expecting boom in cell and gene therapies
- Moving annual total (MAT)
- Immunomedics craters after FDA rejects breast cancer ADC
- NHS England sees off AbbVie's Hep C legal challenge
- J&J’s Erleada cleared for early prostate cancer in Europe
- Unlocking the potential of science and technology in the UK
- A Magical Future – A year on from the graduate scheme
- Rising economic risk casts shadow on Davos meeting
- Vertex gains EU approval for earlier Orkambi use
- Neoantigen player Achilles gets OK for first clinical trial
- Star Europe kicks off 2019 in style
PMHub
Cogora
Cogora has been a leader in healthcare publishing for over 30 years and has become one of the leading full-service...
Latest intelligence
- Unlocking the potential of science and technology in the UK
- Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
- NHS regional footprints
- What to expect from 2019...
- Not another weight-loss ad
- Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
Quick links
Infographics
